Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
The complement system provides critical immunoprotective and immunoregulatory functions but uncontrolled complement activation can lead to severe pathology. In the rare hemolytic disease paroxysmal nocturnal hemoglobinuria (PNH), somatic mutations result in a deficiency of glycosylphosphatidylinositol-linked surface proteins, including the terminal complement inhibitor CD59, on hematopoietic stem cells. In a dysfunctional bone marrow background, these mutated progenitor blood cells expand and populate the periphery. Deficiency of CD59 on PNH red blood cells results in chronic complement-mediated intravascular hemolysis, a process central to the morbidity and mortality of PNH. A recently developed, humanized monoclonal antibody directed against complement component C5, eculizumab (Soliris; Alexion Pharmaceuticals Inc., Cheshire, CT, USA), blocks the proinflammatory and cytolytic effects of terminal complement activation. The recent approval of eculizumab as a first-in-class complement inhibitor for the treatment of PNH validates the concept of complement inhibition as an effective therapy and provides rationale for investigation of other indications in which complement plays a role.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Eculizumab exemplifies a more extreme case. It binds human complement component C5 with high affinity but does not cross-react with rodent C5. Conventional rodent PK and pharmacology studies are therefore essentially uninformative regarding target engagement.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [53]
Citations
Cites
1 retracted
The structure of complement C3b provides insights into complement activation and regulation
Ajees, A. A., Gunasekaran, K., Volanakis, J. E., Narayana, S. V. L., Kotwal, G. J., & Murthy, H. M. K. (2006) · Nature · doi:10.1038/nature05258 · Cited by 70
RetractedHematology: Basic Principles and Practice
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-115-3-238_2 · Cited by 1,857
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Rother, R. P., Bell, L., Hillmen, P., & Gladwin, M. T. (2005) · JAMA · doi:10.1001/jama.293.13.1653 · Cited by 1,557
Walport, M. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104123441506 · Cited by 1,481
ENDOGENOUS NITRIC OXIDE INHIBITS HUMAN PLATELET ADHESION TO VASCULAR ENDOTHELIUM
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91481-4 · Cited by 1,437
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Hillmen, P., Young, N. S., Schubert, J., Brodsky, R. A., Socié, G., Muus, P., Röth, A., Szer, J., Elebute, M. O., Nakamura, R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061648 · Cited by 1,303
Radomski, M. W., Palmer, R. M. J., & Moncada, S. (1987) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1987.tb11367.x · Cited by 1,164
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, T., & Kinoshita, T. (1993) · Cell · doi:10.1016/0092-8674(93)90250-t · Cited by 1,029
Generation of C5a in the absence of C3: a new complement activation pathway
Huber-Lang, M., Sarma, J. V., Zetoune, F. S., Rittirsch, D., Neff, T. A., McGuire, S. R., Lambris, J. D., Warner, R. L., Flierl, M. A., Hoesel, L. M., et al. (2006) · Nature Medicine · doi:10.1038/nm1419 · Cited by 975
Research works printed but not linked: 4
- Male, D., Brostoff, J., Roth, D. & Roitt, I. Immunology (Mosby-Elsevier, Philadelphia, 2006).
- Jain, R.I., Moreland, L.W., Caldwell, J.R., Rollins, S.A. & Mojcik, C.F. A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 42, S77 (1999).
- Tesser, J. et al. Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis. Arthritis Rheum. 44, S274 (2001).
- Rotoli, B. & Luzzatto, L. Paroxysmal nocturnal hemoglobinuria. Semin. Hematol. 26, 201–207 (1989).
Cited by
Complement System Part I – Molecular Mechanisms of Activation and Regulation
Merle, N. S., Church, S. E., Fremeaux-Bacchi, V., & Roumenina, L. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00262 · Cited by 1,620
“The therapeutic monoclonal antibody, Eculizumab, targets human C5 and blocks cleavage by C5 convertases (326).”
BackgroundTerminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome
Legendre, C. M., Licht, C., Muus, P., Greenbaum, L. A., Babu, S., Bedrosian, C., Bingham, C., Cohen, D. J., Delmas, Y., Douglas, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208981 · Cited by 1,586
RETRACTED: Avacopan for the Treatment of ANCA-Associated Vasculitis
Jayne, D. R. W., Merkel, P. A., Schall, T. J., & Bekker, P. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2023386 · Cited by 1,021
RetractedHoward, J. F., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30369-1 · Cited by 845
Therapeutic antibodies for autoimmunity and inflammation
Chan, A. C., & Carter, P. J. (2010) · Nature Reviews Immunology · doi:10.1038/nri2761 · Cited by 837
“Eculizumab lacks the ability to bind FcγRs and activate complement, which are common attributes for human IgG2 and IgG4, respectivel”
BackgroundInternational Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
“Eculizumab prevents the formation of the membrane attack complex and reduces damage caused by complement-fixing AChR antibodies.(36) In a phase II crossover RCT of 14 patients with refractory generalized AChRAb + MG, at the end of the first treatment period, 6/7 (86%) of eculizumab-treated patients achieved the primar…”
ResultParoxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2014) · Blood · doi:10.1182/blood-2014-02-522128 · Cited by 648
“A fewyears later, a genetic mutation (phosphatidylinositol glycan class A [PIGA]) responsible for the GPI anchor protein deficiency was discovered,(8-11) and most recently, a humanized monoclonal antibody that inhibits terminal complement activation has been shown to ameliorate hemolysis and thrombosis and improve qua…”
Self-citationUse of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies
on behalf of the French Study Group for aHUS/C3G, Zuber, J., Fakhouri, F., Roumenina, L. T., Loirat, C., & Frémeaux-Bacchi, V. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.214 · Cited by 496
COVID-19 cytokine storm: the anger of inflammation
Mahmudpour, M., Roozbeh, J., Keshavarz, M., Farrokhi, S., & Nabipour, I. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155151 · Cited by 461
“Eculizumab is a monoclonal antibody with high affinity to C5 near its cleavage site [128].”
Paroxysmal nocturnal haemoglobinuria
Hill, A., DeZern, A. E., Kinoshita, T., & Brodsky, R. A. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.28 · Cited by 448
Lee, J. W., Sicre de Fontbrune, F., Wong Lee Lee, L., Pessoa, V., Gualandro, S., Füreder, W., Ptushkin, V., Rottinghaus, S. T., Volles, L., Shafner, L., et al. (2019) · Blood · doi:10.1182/blood-2018-09-876136 · Cited by 416
Inflammogenesis of Secondary Spinal Cord Injury
Anwar, M. A., Al Shehabi, T. S., & Eid, A. H. (2016) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2016.00098 · Cited by 440
“Thus, Eculizumab antagonizes the formation of C5b-9 (MAC), and this effectively reduces hemolysis in the patients (Rother et al., 2007; Brodsky et al., 2008).”
BackgroundComplement, a target for therapy in inflammatory and degenerative diseases
Morgan, B. P., & Harris, C. L. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4657 · Cited by 431
“The C5-specific mAb eculizumab binds to C5 remote from the cleavage site, at a site in the α-chain that prevents C5 from binding to C5 convertase 24, 25, 149 .”
BackgroundComplement and Its Receptors: New Insights into Human Disease
Holers, V. M. (2014) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032713-120154 · Cited by 430
“On red blood cells, the absence of DAF allows alternative pathway–initiated complement activation by C3 and C5 convertases; the absence of CD59 allows activated C5 to proceed to form the MAC, resulting in intravascular hemolysis (102, 103).”
BackgroundLicht, C., Greenbaum, L. A., Muus, P., Babu, S., Bedrosian, C. L., Cohen, D. J., Delmas, Y., Douglas, K., Furman, R. R., Gaber, O. A., et al. (2015) · Kidney International · doi:10.1038/ki.2014.423 · Cited by 420
Genetic Variants in C5 and Poor Response to Eculizumab
Nishimura, J.-I., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A. L., Noji, H., Kitamura, K., Eto, T., Takahashi, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1311084 · Cited by 417
Borowitz, M. J., Craig, F. E., DiGiuseppe, J. A., Illingworth, A. J., Rosse, W., Sutherland, D. R., Wittwer, C. T., & Richards, S. J. (2010) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20525 · Cited by 403
“In the last few years, the development (9) and successful clinical trial (10) of a humanized monoclonal antibody against the terminal complement protein C5 (Eculizumab; Alexion Pharmaceuticals, Cheshire, CT) has improved the quality of life for patients with hemolytic PNH by reducing hemolysis, thrombosis, and transfu…”
BackgroundTherapeutic siRNA: State-of-the-Art and Future Perspectives
Friedrich, M., & Aigner, A. (2022) · BioDrugs · doi:10.1007/s40259-022-00549-3 · Cited by 396
“Consequently, the formation of the membrane attack complex and the release of the C5a anaphylatoxin are prevented [133, 134].”
BackgroundHillmen, P., Muus, P., Röth, A., Elebute, M. O., Risitano, A. M., Schrezenmeier, H., Szer, J., Browne, P., Maciejewski, J. P., Schubert, J., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12347 · Cited by 394
“Although eculizumab suppresses the terminal complement system, the proximal complement system, responsible for opsonization of microorganisms and clearance of immune complexes, remains intact and fully functional (Rother et al, 2007).”
BackgroundPittock, S. J., Lennon, V. A., McKeon, A., Mandrekar, J., Weinshenker, B. G., Lucchinetti, C. F., O'Toole, O., & Wingerchuk, D. M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70076-0 · Cited by 395
The renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Risitano, A. M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., Alfinito, F., Camera, A., Gianfaldoni, G., et al. (2009) · Blood · doi:10.1182/blood-2008-11-189944 · Cited by 361
IgG Fc engineering to modulate antibody effector functions
Wang, X., Mathieu, M., & Brezski, R. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0473-8 · Cited by 356
“The approved anti-C5 therapeutic, eculizumab, has the IgG2 amino acids 118 to 260 and the IgG4 amino acids 261 to 447 and has been shown to have limited or undetectable effector function (Rother et al., 2007).”
BackgroundAtypical Hemolytic Uremic Syndrome
Kavanagh, D., Goodship, T. H., & Richards, A. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2013.08.003 · Cited by 348
“Eculizumab, a recombinant humanized monoclonal antibody directed against C5, blocks the cleavage of C5 into its effector components C5a and C5b.(106) Since the initial use of this complement inhibitor in aHUS in 2009,(107) the effectiveness of eculizumab has been communicated in many case reports, meeting abstracts, a…”
Clinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life
Saunders, K. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01296 · Cited by 316
“To silence the effector functions of Fc, large portions of Fc regions from different subclasses have been exchanged to generate crosssubclass Fc regions (141).”
BackgroundInfluentialFakhouri, F., Hourmant, M., Campistol, J. M., Cataland, S. R., Espinosa, M., Gaber, A. O., Menne, J., Minetti, E. E., Provôt, F., Rondeau, E., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.12.034 · Cited by 305
“Forty-six percent of patients have already reached ESRD by the time aHUS is diagnosed,5 and the risk for kidney failure and death increases with disease duration.4,5 More rarely, TMA in aHUS also leads to significant morbidity in other vital organ systems, including neurologic, cardiovascular, pulmonary, and gastroint…”
BackgroundConsiderations for the Design of Antibody-Based Therapeutics
Goulet, D. R., & Atkins, W. M. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.05.031 · Cited by 302
Atypical aHUS: State of the art
Nester, C. M., Barbour, T., de Cordoba, S. R., Dragon-Durey, M. A., Fremeaux-Bacchi, V., Goodship, T. H. J., Kavanagh, D., Noris, M., Pickering, M., Sanchez-Corral, P., et al. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.03.246 · Cited by 299
Current progress in innovative engineered antibodies
Strohl, W. R. (2018) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 279
“…the CTLA4-Fc fusion proteins, abatacept (Orencia®) and belatacept (Nujolix®), both of which have modified hinges to reduce Fc functionality (Davis et al., 2007), and the humanized anti-C5 mAb, eculizumab (Soliris®), which has an IgG2/IgG4 hybrid Fc to reduce Fc functionality (Rother et al., 2007).”
BackgroundFonseca, M. I., Ager, R. R., Chu, S.-H., Yazan, O., Sanderson, S. D., LaFerla, F. M., Taylor, S. M., Woodruff, T. M., & Tenner, A. J. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901005 · Cited by 268
“PMX205 has an added advantage over a Food and Drug Administration-approved anti-C5 mAb (69) or the C5-specific inhibitor from the soft tick (70) (in addition to its smaller molecular size) in that both of the latter prevent cleavage of C5 (thereby preventing C5a and C5b-9 generation), while PMX205 permits the generati…”
BackgroundCampistol, J. M., Arias, M., Ariceta, G., Blasco, M., Espinosa, L., Espinosa, M., Grinyó, J. M., Macía, M., Mendizábal, S., Praga, M., et al. (2015) · Nefrología · doi:10.1016/j.nefro.2015.07.005 · Cited by 272
The next generation of therapeutics for chronic kidney disease
Breyer, M. D., & Susztak, K. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.67 · Cited by 272
Treatment strategies for autoimmune encephalitis
Shin, Y.-W., Lee, S.-T., Park, K.-I., Jung, K.-H., Jung, K.-Y., Lee, S. K., & Chu, K. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617722347 · Cited by 266
How I treat paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2009) · Blood · doi:10.1182/blood-2009-03-195966 · Cited by 263
Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis
Muppidi, S., Utsugisawa, K., Benatar, M., Murai, H., Barohn, R. J., Illa, I., Jacob, S., Vissing, J., Burns, T. M., Kissel, J. T., et al. (2019) · Muscle & Nerve · doi:10.1002/mus.26447 · Cited by 262
“Inhibition of terminal complement activity with eculizumab is a biologically rational approach to prevent damage at the neuromuscular junction in patients with AChR refractory gMG.(22) Eculizumab has been reported to produce rapid and clinically meaningful improvements in activities of daily living, muscle strength, f…”
BackgroundRisitano, A. M., Marotta, S., Ricci, P., Marano, L., Frieri, C., Cacace, F., Sica, M., Kulasekararaj, A., Calado, R. T., Scheinberg, P., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01157 · Cited by 224
“Treatment options for hemolytic PNH remained limited and often inadequate until eculizumab became available, a humanized monoclonal antibody (mAb) targeting the component 5 (C5) of the complement cascade (17).”
BackgroundSheridan, D., Yu, Z.-X., Zhang, Y., Patel, R., Sun, F., Lasaro, M. A., Bouchard, K., Andrien, B., Marozsan, A., Wang, Y., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0195909 · Cited by 251
Molecular engineering and design of therapeutic antibodies
Presta, L. G. (2008) · Current Opinion in Immunology · doi:10.1016/j.coi.2008.06.012 · Cited by 250
Socié, G., Caby‐Tosi, M., Marantz, J. L., Cole, A., Bedrosian, C. L., Gasteyger, C., Mujeebuddin, A., Hillmen, P., Vande Walle, J., & Haller, H. (2019) · British Journal of Haematology · doi:10.1111/bjh.15790 · Cited by 239
“Meningococcal infections are of particular interest because there is a well-established and predictable risk of infection from Neisseria species that is directly related to the mechanism of action of eculizumab (Rother et al, 2007; McNamara et al, 2017).”
BackgroundInfluentialHillmen, P., Elebute, M., Kelly, R., Urbano‐Ispizua, A., Hill, A., Rother, R. P., Khursigara, G., Fu, C., Omine, M., Browne, P., et al. (2010) · American Journal of Hematology · doi:10.1002/ajh.21757 · Cited by 205
“Eculizumab (Soliris(1)) is a humanized monoclonal antibody that targets complement protein C5, thereby preventing production of the potent proinflammatory mediator C5a and the assembly of the terminal complement complex (also called the membrane attack complex) during complement activation [24].”
BackgroundHoward, J. F., Barohn, R. J., Cutter, G. R., Freimer, M., Juel, V. C., Mozaffar, T., Mellion, M. L., Benatar, M. G., Farrugia, M. E., Wang, J. J., et al. (2013) · Muscle & Nerve · doi:10.1002/mus.23839 · Cited by 225
“For example, antibody blockade of AChR function5,9 occurs when antibodies bind to a number of epitopes on the receptor complex, including the direct binding site for acetylcholine.5 Antibody binding to the AChR complex initiates several destructive processes, including accelerated endocytosis and degradation of AChR a…”
BackgroundThe role of complement in antibody-mediated rejection in kidney transplantation
Stegall, M. D., Chedid, M. F., & Cornell, L. D. (2012) · Nature Reviews Nephrology · doi:10.1038/nrneph.2012.212 · Cited by 224
Therapeutic potential of complement modulation
Wagner, E., & Frank, M. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3011 · Cited by 218
“Eculizumab is a monoclonal antibody specific for C5 that effectively inhibits C5a generation and MAC formatio”
BackgroundThe role of the immune system in Alzheimer disease: Etiology and treatment
Jevtic, S., Sengar, A. S., Salter, M. W., & McLaurin, J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.08.005 · Cited by 215
Eculizumab in the Treatment of Membranoproliferative Glomerulonephritis
Bomback, A. S. (2014) · Nephron Clinical Practice · doi:10.1159/000368592 · Cited by 216
Myasthenia gravis: the role of complement at the neuromuscular junction
Howard, J. F. (2018) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13522 · Cited by 213
Potential aggregation prone regions in biotherapeutics: A survey of commercial monoclonal antibodies
Wang, X., Das, T. K., Singh, S. K., & Kumar, S. (2009) · mAbs · doi:10.4161/mabs.1.3.8035 · Cited by 198
How I treat paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2021) · Blood · doi:10.1182/blood.2019003812 · Cited by 196
The spectrum of complement alternative pathway‐mediated diseases
Holers, V. M. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00641.x · Cited by 195
“Thus, although the anti-C5 mAb eculizumab is an approved therapy for this disease (2), additional therapeutic effects may be found by inhibition of the alternative pathway.”
BackgroundRisitano, A. M., Ricklin, D., Huang, Y., Reis, E. S., Chen, H., Ricci, P., Lin, Z., Pascariello, C., Raia, M., Sica, M., et al. (2014) · Blood · doi:10.1182/blood-2013-11-536573 · Cited by 194
Complement in human disease: approved and up-and-coming therapeutics
West, E. E., Woodruff, T., Fremeaux-Bacchi, V., & Kemper, C. (2024) · The Lancet · doi:10.1016/s0140-6736(23)01524-6 · Cited by 182
Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity
Tacken, P. J., Zeelenberg, I. S., Cruz, L. J., van Hout-Kuijer, M. A., van de Glind, G., Fokkink, R. G., Lambeck, A. J. A., & Figdor, C. G. (2011) · Blood · doi:10.1182/blood-2011-07-367615 · Cited by 173
Optimization of Fc-mediated effector functions of monoclonal antibodies
Strohl, W. R. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.011 · Cited by 168
Yuen, J., Pluthero, F. G., Douda, D. N., Riedl, M., Cherry, A., Ulanova, M., Kahr, W. H. A., Palaniyar, N., & Licht, C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00137 · Cited by 163
“, eculizumab) are now available for clinical use (41, 42).”
BackgroundCompendium of current complement therapeutics
Zelek, W. M., Xie, L., Morgan, B. P., & Harris, C. L. (2019) · Molecular Immunology · doi:10.1016/j.molimm.2019.07.030 · Cited by 163
Eculizumab for paroxysmal nocturnal haemoglobinuria
Parker, C. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60001-5 · Cited by 164
The Role of the Complement System and the Activation Fragment C5a in the Central Nervous System
Woodruff, T. M., Ager, R. R., Tenner, A. J., Noakes, P. G., & Taylor, S. M. (2010) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8085-y · Cited by 161
Paroxysmal Nocturnal Hemoglobinuria
Rotoli, B., Nafa, K., & Risitano, A. M. (2007) · Principles of Molecular Medicine · doi:10.1007/978-1-59259-963-9_86 · Cited by 161
Targeting the complement system for the management of retinal inflammatory and degenerative diseases
Xu, H., & Chen, M. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.001 · Cited by 160
“Eculizumab, another C5 speci fi c mAb, had been approved for the treatment of PNH and atypical hemolytic uremic syndrome (aHUS) (Rother et al., 2007).”
BackgroundCompstatin: A Complement Inhibitor on its Way to Clinical Application
Ricklin, D., & Lambris, J. D. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-78952-1_20 · Cited by 162
“…the quest for complement-specific therapeutics therapeutic antibody eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.) against paroxysmal nocturnal hemoglobinuria, the first drug with proven complement connectivity has been marketed only recently (Ricklin and Lambris 2007a; Rother et al. 2007).”
Role of Complement and Complement Regulatory Proteins in the Complications of Diabetes
Ghosh, P., Sahoo, R., Vaidya, A., Chorev, M., & Halperin, J. A. (2015) · Endocrine Reviews · doi:10.1210/er.2014-1099 · Cited by 154
Pathology after Eculizumab in Dense Deposit Disease and C3 GN
Herlitz, L., Bomback, A. S., Markowitz, G. S., Stokes, M. B., Smith, R. N., Colvin, R. B., Appel, G. B., & D’Agati, V. D. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011121186 · Cited by 155
Lonze, B. E., Zachary, A. A., Magro, C. M., Desai, N. M., Orandi, B. J., Dagher, N. N., Singer, A. L., Carter-Monroe, N., Nazarian, S. M., Segev, D. L., et al. (2014) · American Journal of Transplantation · doi:10.1111/ajt.12540 · Cited by 156
Treatment-Refractory Myasthenia Gravis
Silvestri, N. J., & Wolfe, G. I. (2014) · Journal of Clinical Neuromuscular Disease · doi:10.1097/cnd.0000000000000034 · Cited by 151
“and membrane attack complex–mediated cell activation and lysis.(34) The role of comple-”
BackgroundThe Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
Gogesch, P., Dudek, S., van Zandbergen, G., Waibler, Z., & Anzaghe, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168947 · Cited by 172
“The α-C5 mAb eculizumab is the first approved cross-isotype mAb, which has the amino acids 118–260 of IgG2 and the amino acids 261–447 of IgG4 resulting in limited or undetectable Fc-mediated effector functions [124].”
BackgroundHarder, M. J., Kuhn, N., Schrezenmeier, H., Höchsmann, B., von Zabern, I., Weinstock, C., Simmet, T., Ricklin, D., Lambris, J. D., Skerra, A., et al. (2016) · Blood · doi:10.1182/blood-2016-08-732800 · Cited by 168
Loschi, M., Porcher, R., Barraco, F., Terriou, L., Mohty, M., de Guibert, S., Mahe, B., Lemal, R., Dumas, P., Etienne, G., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24278 · Cited by 148
“Eculizumab is a monoclonal humanized antibody that inhibits terminal complement activity [7].”
BackgroundRiedl, M., Fakhouri, F., Quintrec, M. L., Noone, D. G., Jungraithmayr, T., Frémeaux‐Bacchi, V., & Licht, C. P. B. (2014) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1376153 · Cited by 156
Brodsky, R. A., Luznik, L., Bolaños‐Meade, J., Leffell, M. S., Jones, R. J., & Fuchs, E. J. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.203 · Cited by 143
aHUS caused by complement dysregulation: new therapies on the horizon
Waters, A. M., & Licht, C. P. B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1556-4 · Cited by 143
“In animal studies, eculizumab was found to cross the placental barrier and show fetal morbidity and mortality [117].”
BackgroundSutherland, D. R., Keeney, M., & Illingworth, A. J. (2012) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21023 · Cited by 153
“Over the last few years, a humanized monoclonal antibody against the terminal complement protein C5 (29) (Eculizumab; Alexion, Cheshire, CT) has been approved for the treatment of patients with hemolytic PNH.”
BackgroundStructure of and influence of a tick complement inhibitor on human complement component 5
Fredslund, F., Laursen, N. S., Roversi, P., Jenner, L. B., Oliveira, C. L. P., Pedersen, J. S., Nunn, M. A., Lea, S. M., DiScipio, R. G., Sottrup‐Jensen, L., et al. (2008) · Nature Immunology · doi:10.1038/ni.1625 · Cited by 134
“The development of C5-specific inhibitors is desirable, as only the terminal complement components would be affected, whereas the beneficial immunoprotective and immunoregulatory effects mediated by 'upstream' complement components would remain functiona”
BackgroundDmytrijuk, A., Robie‐Suh, K., Cohen, M. H., Rieves, D., Weiss, K., & Pazdur, R. (2008) · The Oncologist · doi:10.1634/theoncologist.2008-0086 · Cited by 134
“Cheshire, CT) is a humanized monoclonal antibody that binds to the human C5 complement protein with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventingthegenerationoftheterminalcomplementcomplex C5b-9 (membrane attack complex), responsible for the lysis of PNH RBCs lacking cell surface termina…”
BackgroundHypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk
Kearney, K., Tomlinson, D., Smith, K., & Ajjan, R. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0515-9 · Cited by 130
“Complement C3 as a drug target Therapeutic intervention in the complement system has been recognised as a potential strategy for the treatment of a series of inflammatory and autoimmune diseases [186, 187] whilst the role of C3 in fibrinolysis has yet to be widely recognised as an antithrombotic therapeutic target.”
BackgroundPharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals
Menon, D., & Bril, V. (2022) · Drugs · doi:10.1007/s40265-022-01726-y · Cited by 140
“This was approved for treatment of paroxysmal nocturnal haemoglobinuria (PNH), a complement mediated disorder, in 2007 [132, 133].”
BackgroundOrandi, B. J., Zachary, A. A., Dagher, N. N., Bagnasco, S. M., Garonzik‐Wang, J., Arendonk, K. J. V., Gupta, N., Lonze, B. E., Alachkar, N., Kraus, E. S., et al. (2014) · Transplantation · doi:10.1097/tp.0000000000000298 · Cited by 123
“The latter is required for membrane attack complex formation and cell lysis (8).”
BackgroundTherapeutic monoclonal antibodies and derivatives: Historical perspectives and future directions
Rodgers, K. R., & Chou, R. C. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.07.004 · Cited by 155
Myasthenia gravis: the future is here
Kaminski, H. J., Sikorski, P. M., Coronel, S. I., & Kusner, L. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179742 · Cited by 146
C5a Mediates Peripheral Blood Neutrophil Dysfunction in Critically Ill Patients
Morris, A. C., Kefala, K., Wilkinson, T. S., Dhaliwal, K., Farrell, L., Walsh, T. S., MacKenzie, S. J., Reid, H., Davidson, D. J., Haslett, C., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200812-1928oc · Cited by 123
“In this regard anti-C5 and anti-CD88 therapies do exist (44, 45).”
Risitano, A. M., Notaro, R., Pascariello, C., Sica, M., del Vecchio, L., Horvath, C. J., Fridkis-Hareli, M., Selleri, C., Lindorfer, M. A., Taylor, R. P., et al. (2012) · Blood · doi:10.1182/blood-2011-12-398792 · Cited by 122
Fridkis‐Hareli, M., Storek, M., Mazsaroff, I., Risitano, A. M., Lundberg, A. S., Horvath, C. J., & Holers, V. M. (2011) · Blood · doi:10.1182/blood-2011-06-359646 · Cited by 121
Fit for the Eye: Aptamers in Ocular Disorders
Drolet, D. W., Green, L. S., Gold, L., & Janjić, N. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0573 · Cited by 130
“An inhibitor of proteolytic activation of C5 was considered a promising complement therapeutic since it could prevent an injury of this type while preserving upstream complement defense and clearance pathways [145,147,148].”
BackgroundImmunological Basis of the Endometriosis: The Complement System as a Potential Therapeutic Target
Agostinis, C., Balduit, A., Mangogna, A., Zito, G., Romano, F., Ricci, G., Kishore, U., & Bulla, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599117 · Cited by 124
“Food and Drug Administration (FDA) approved Eculizumab (anti-C5 antibody) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in 2007 (125), 40 years after the demonstration that complement was the principal cause of this devastating disease (126, 127).”
BackgroundLong-term efficacy of the complement inhibitor eculizumab in cold agglutinin disease
Röth, A., Hüttmann, A., Rother, R. P., Dührsen, U., & Philipp, T. (2009) · Blood · doi:10.1182/blood-2009-01-196329 · Cited by 112
Complement dysregulation and disease: From genes and proteins to diagnostics and drugs
de Córdoba, S. R., Tortajada, A., Harris, C. L., & Morgan, B. P. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.07.021 · Cited by 123
Baines, A. C., & Brodsky, R. A. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.02.003 · Cited by 120
Recent developments in low molecular weight complement inhibitors
Qu, H., Ricklin, D., & Lambris, J. D. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.08.032 · Cited by 109
“Food and Drug Administration (FDA) recently approved human C1-Inh (Cinryze, ViroPharma) for hereditary angioedema (Cocchio and Marzella, 2009) and eculizumab (Soliris, Alexion Pharmaceuticals), a humanized anti-C5 monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria caused by an absence of the…”
Complement: The Emerging Architect of the Developing Brain
Coulthard, L. G., Hawksworth, O. A., & Woodruff, T. M. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.03.009 · Cited by 119
Heesterbeek, D. A. C., Bardoel, B. W., Parsons, E. S., Bennett, I., Ruyken, M., Doorduijn, D. J., Gorham, R. D., Berends, E. T. M., Pyne, A. L. B., Hoogenboom, B. W., et al. (2019) · The EMBO Journal · doi:10.15252/embj.201899852 · Cited by 114
Nogueras-Ortiz, C. J., Mahairaki, V., Delgado-Peraza, F., Das, D., Avgerinos, K., Eren, E., Hentschel, M., Goetzl, E. J., Mattson, M. P., & Kapogiannis, D. (2020) · Cells · doi:10.3390/cells9071618 · Cited by 106
“Complement inhibitors are already under development for various clinical applications—for example, eculizumab is a well-tolerated monoclonal antibody that inhibits C5 and is being used in paroxysmal nocturnal hemoglobinuria [86], whereas a monoclonal antibody against C1q is well-tolerated in healthy volunteers and is…”
BackgroundSoluble ligands as drug targets
Attwood, M. M., Jonsson, J., Rask‐Andersen, M., & Schiöth, H. B. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0078-4 · Cited by 120
Michael, M., Bagga, A., Sartain, S. E., & Smith, R. J. H. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01202-8 · Cited by 130
Fukuzawa, T., Sampei, Z., Haraya, K., Ruike, Y., Shida-Kawazoe, M., Shimizu, Y., Gan, S. W., Irie, M., Tsuboi, Y., Tai, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01087-7 · Cited by 107
Mannes, M., Dopler, A., Zolk, O., Lang, S. J., Halbgebauer, R., Höchsmann, B., Skerra, A., Braun, C., Huber-Lang, M. S., Schrezenmeier, H., et al. (2020) · Blood · doi:10.1182/blood.2020005959 · Cited by 116
Vaught, A. “. J., Gavriilaki, E., Hueppchen, N. A., Blakemore, K. J., Yuan, X., Seifert, S. M., York, S., & Brodsky, R. A. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.01.005 · Cited by 114
“Unlike HELLP, where the mainstay of therapy is limited to supportive care, expectant management and ultimately delivery, aHUS is treated with a C5 monoclonal antibody, eculizumab [19].”
BackgroundEndothelial cells: source, barrier, and target of defensive mediators
Roumenina, L. T., Rayes, J., Frimat, M., & Fremeaux‐Bacchi, V. (2016) · Immunological Reviews · doi:10.1111/imr.12479 · Cited by 106
Complement in hemolytic anemia
Brodsky, R. A. (2015) · Blood · doi:10.1182/blood-2015-06-640995 · Cited by 112
An open label clinical trial of complement inhibition in multifocal motor neuropathy
Fitzpatrick, A., Mann, C., Barry, S., Brennan, K., Overell, J. R., & Willison, H. J. (2011) · Journal of the Peripheral Nervous System · doi:10.1111/j.1529-8027.2011.00328.x · Cited by 104
“lysis via membrane attack complex (MAC) (Rother et al., 2007).”
BackgroundInfluentialIgG2m4, an engineered antibody isotype with reduced Fc function
An, Z., Forrest, G., Moore, R., Cukan, M., Haytko, P., Huang, L., Vitelli, S., Zhao, J. Z., Lu, P., Hua, J., et al. (2009) · mAbs · doi:10.4161/mabs.1.6.10185 · Cited by 102
Metadata
- Authors
- Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L.
- Affiliations
- Alexion Pharmaceuticals (United States) (US)
- Johns Hopkins University (US)
- Corresponding author
- Rother, Russell P
- Venue
- Nature Biotechnology
- Published
- 2007-11
- Volume
- 25
- Issue
- 11
- Pages
- 1256-1264
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2004265876
- Cited by
- 778
- References
- 88
- Citations by year
- 2026: 34 · 2025: 38 · 2024: 43 · 2023: 58 · 2022: 34 · 2021: 47 · 2020: 59 · 2019: 49 · 2018: 42 · 2017: 52 · 2016: 60 · 2015: 39 · 2014: 41 · 2013: 38 · 2012: 43
- FWCI
- 8.68
- Type
- journal article
- Language
- en
- Update notices
- erratum (2007-12-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Complement system in diseases
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- eculizumab, paroxysmal nocturnal hemoglobinuria, complement inhibition, complement component C5, CD59, intravascular hemolysis, monoclonal antibodies, glycosylphosphatidylinositol deficiency, terminal complement activation, drug development
- MeSH terms
- Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Complement C5, Drug Evaluation, Preclinical, Hemoglobinuria, Paroxysmal, Humans, Drug Design, Protein Engineering, Drug Approval, Complement Inactivating Agents, Mice, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.